Transferrin-PEG-PE modified dexamethasone conjugated cationic lipid carrier mediated gene delivery system for tumor-targeted transfection

International Journal of Nanomedicine

Volumn 7, Issue , 2012, Pages 2513-2522

  Wang, Wei ^a   Zhou, Fang ^a   Ge, Linfu ^a   Liu, Ximin ^a   Kong, Fansheng ^a  

^a JINAN MILITARY GENERAL HOSPITAL   (China)

Author keywords

Active targeting; Dexamethasone conjugated lipid; Gene delivery; Nuclear localization; Transferrin PEG PE

Indexed keywords

6 LAUROXYHEXYL ORNITHINATE; DEXAMETHASONE 21 MESILATE; DRUG CARRIER; ENHANCED GREEN FLUORESCENT PROTEIN; PLASMID VECTOR; SOLID LIPID NANOPARTICLE; TRANSFERRIN POLYETHYLENE GLYCOL PHOSPHATIDYLETHANOLAMINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL STRAIN HEPG2; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG EFFICACY; DRUG SCREENING; DRUG STRUCTURE; GENETIC MODEL; HEPATOMA CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NUCLEAR LOCALIZATION SIGNAL; PARTICLE SIZE; PROCESS DEVELOPMENT; PROCESS OPTIMIZATION; PROTON NUCLEAR MAGNETIC RESONANCE; TARGET CELL; ZETA POTENTIAL;

ANIMALS; CELL LINE, TUMOR; CELL SURVIVAL; DEXAMETHASONE; DNA; GREEN FLUORESCENT PROTEINS; HUMANS; MICE; MICE, INBRED BALB C; MICROSCOPY, FLUORESCENCE; NANOPARTICLES; PHOSPHATIDYLETHANOLAMINES; POLYETHYLENE GLYCOLS; TRANSFECTION; TRANSFERRIN;

ANIMALIA;

EID: 84870342369     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S31915     Document Type: Article

References (51)

1. Kong F, Zhou F, Ge L, Liu X, Wang Y. Mannosylated liposomes for targeted gene delivery. Int J Nanomedicine. 2012;7:1079-1089.
2. Kong F, Ge L, Liu X, Huang N, Zhou F. Mannan-modified PLGA nanoparticles for targeted gene delivery. Int J Photoenergy. 2012;Article ID 926754:7 pages. doi:10.1155/2012/926754.
3. Xie S, Pan B, Shi B, et al. Solid lipid nanoparticle suspension enhanced the therapeutic efficacy of praziquantel against tapeworm. Int J Nanomedicine. 2011;6:2367-2374.
4. Ma K, Hu M, Qi Y, et al. Structure-transfection activity relationships with glucocorticoid-polyethyl-enimine conjugate nuclear gene delivery systems. Biomaterials. 2009;30(22):3780-3789.
5. Atkinson H, Chalmers R. Delivering the goods: viral and non-viral gene therapy systems and the inherent limits on cargo DNA and internal sequences. Genetica. 2010;138(5):485-498.
6. Choi JS, Ko KS, Park JS, Kim YH, Kim SW, Lee M. Dexamethasone conjugated poly(amidoamine) dendrimer as a gene carrier for efficient nuclear translocation. Int J Pharm. 2006;320(1-2):171-178.
7. Nishikawa M, Huang L. Nonviral vectors in the new millennium: delivery barriers in gene transfer. Hum Gene Ther. 2001;12(8):861-870.
8. Torchilin VP. Multifunctional nanocarriers. Adv Drug Deliv Rev. 2006;58(14):1532-1555.
9. Wagner E, Ogris M, Zauner W. Polylysine-based transfection systems utilizing receptor-mediated delivery. Adv Drug Deliv Rev. 1998; 30(1-3):97-113.
10. Ma K, Hu MX, Qi Y, et al. PAMAM-triamcinolone acetonide conjugate as a nucleus-targeting gene carrier for enhanced transfer activity. Biomaterials. 2009;30(30):6109-6118.
11. Lo WL, Chien Y, Chiou GY, et al. Nuclear localization signal-enhanced RNA interference of EZH2 and Oct4 in the eradication of head and neck squamous cell carcinoma-derived cancer stem cells. Biomaterials. 2012;33(14):3693-3709.
12. Yu VC, Naar AM, Rosenfeld MG. Transcriptional regulation by the nuclear receptor superfamily. Curr Opin Biotechnol. 1992;3(6): 597-602.
13. Adcock IM, Caramori G. Cross-talk between pro-inflammatory transcription factors and glucocorticoids. Immunol Cell Biol. 2001;79(4):376-384.
14. Shahin V, Albermann L, Schillers H, et al. Steroids dilate nuclear pores imaged with atomic force microscopy. J Cell Physiol. 2005;202(2): 591-601.
15. Strübing C, Clapham DE. Active nuclear import and export is independent of lumenal Ca2oostores in intact mammalian cells. J Gen Physiol. 1999;113(2):239-248.
16. Rebuffat A, Bernasconi A, Ceppi M, et al. Selective enhancement of gene transfer by steroid-mediated gene delivery. Nat Biotechnol. 2001;19(12):1155-1161.
17. Kim H, Bae YM, Kim HA, et al. Synthesis and characterization of dexamethasone-conjugated linear polyethylenimine as a gene carrier. J Cell Biochem. 2010;110(3):743-751.
18. Kastrup L, Oberleithner H, Ludwig Y, Schafer C, Shahin V. Nuclear envelope barrier leak induced by dexamethasone. J Cell Physiol. 2006;206(2):428-434.
19. Kim H, Kim HA, Bae YM, Choi JS, Lee M. Dexamethasone-conjugated polyethylenimine as an efficient gene carrier with an anti-apoptotic effect to cardiomyocytes. J Gene Med. 2009;11(6):515-522.
20. Mi Bae Y, Choi H, Lee S, et al. Dexamethasone-conjugated low molecular weight polyethylenimine as a nucleus-targeting lipopolymer gene carrier. Bioconjug Chem. 2007;18(6):2029-2036.
21. Olbrich C, Bakowsky U, Lehr CM, Muller RH, Kneuer C. Cationic solid-lipid nanoparticles can efficiently bind and transfect plasmid DNA. J Control Release. 2001;77(3):345-355.
22. Vighi E, Ruozi B, Montanari M, Battini R, Leo E. Re-dispersible cationic solid lipid nanoparticles (SLNs) freeze-dried without cryoprotectors: characterization and ability to bind the pEGFP-plasmid. Eur J Pharm Biopharm. 2007;67(2):320-328.
23. Yu W, Liu C, Ye J, Zou W, Zhang N, Xu W. Novel cationic SLN containing a synthesized single-tailed lipid as a modifier for gene delivery. Nanotechnology. 2009;20(21):215102.
24. Yu W, Liu C, Liu Y, Zhang N, Xu W. Mannan-modified solid lipid nanoparticles for targeted gene delivery to alveolar macrophages. Pharm Res. 2010;27(8):1584-1596.
25. Lobovkina T, Jacobson GB, Gonzalez-Gonzalez E, et al. In vivo sustained release of siRNA from solid lipid nanoparticles. ACS Nano. 2011;5(12):9977-9983.
26. Doktorovova S, Shegokar R, Rakovsky E, et al. Cationic solid lipid nanoparticles (cSLN): structure, stability and DNA binding capacity correlation studies. Int J Pharm. 2011;420(2):341-349.
27. Oster CG, Kim N, Grode L, et al. Cationic microparticles consisting of poly(lactide-co-glycolide) and polyethylenimine as carriers systems for parental DNA vaccination. J Control Release. 2005;104(2):359-377.
28. Pinnaduwage P, Schmitt L, Huang L. Use of a quaternary ammonium detergent in liposome mediated DNA transfection of mouse L-cells. Biochim Biophys Acta. 1989;985(1):33-37.
29. Tabatt K, Sameti M, Olbrich C, Müller RH, Lehr CM. Effect of cationic lipid and matrix lipid composition on solid lipid nanoparticle-mediated gene transfer. Eur J Pharm Biopharm. 2004;57(2):155-162.
30. Tang F, Hughes JA. Synthesis of a single-tailed cationic lipid and investigation of its transfection. J Control Release. 1999;62(3):345-358.
31. Gilot D, Miramon ML, Benvegnu T, et al. Cationic lipids derived from glycine betaine promote efficient and non-toxic gene transfection in cultured hepatocytes. J Gene Med. 2002;4(4):415-427.
32. Lukyanov AN, Gao Z, Mazzola L, Torchilin VP. Polyethylene glycol-diacyllipid micelles demonstrate increased accumulation in subcutaneous tumors in mice. Pharm Res. 2002;19(10):1424-1429.
33. Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov. 2005;4(2):145-160.
34. Jiang Z, Sun C, Yin Z, et al. A comparison of two kinds of nanomedicine for targeted gene therapy: Pre-modified or post-modified gene delivery systems. Int J Nanomedicine. 2012;7:2019-2031.
35. Singh M. Transferrin as a targeting ligand for liposomes and anticancer drugs. Curr Pharm Des. 1999;5(6):443-451.
36. Bellocq NC, Pun SH, Jensen GS, Davis ME. Transferrin-containing, cyclodextrin polymer-based particles for tumor-targeted gene delivery. Bioconjug Chem. 2003;14(6):1122-1132.
37. Wagner E, Curiel D, Cotton M. Delivery of drugs, proteins and genes into cells using transferrin as a ligand for receptor-mediated endocytosis. Adv Drug Deliv Rev. 1994;14:113-135.
38. Li H, Qian ZM. Transferrin/transferrin receptor-mediated drug delivery. Med Res Rev. 2002;22(3):225-250.
39. Maruyama K. Intracellular targeting delivery of liposomal drugs to solid tumors based on EPR effects. Adv Drug Deliv Rev. 2011;63(3): 161-169.
40. Jiang YY, Liu C, Hong MH, Zhu SJ, Pei YY. Tumor cell targeting of transferrin-PEG-TNF-alpha conjugate via a receptor-mediated delivery system: design, synthesis, and biological evaluation. Bioconjug Chem. 2007;18(1):41-49.
41. Liu C, Yu W, Chen Z, Zhang J, Zhang N. Enhanced gene transfection efficiency in CD13-positive vascular endothelial cells with targeted poly(lactic acid)-poly(ethylene glycol) nanoparticles through caveolaemediated endocytosis. J Control Release. 2011;151(2):162-175.
42. Suzuki R, Takizawa T, Kuwata Y, et al. Effective anti-tumor activity of oxaliplatin encapsulated in transferrin-PEG-liposome. Int J Pharm. 2008;346(1-2):143-150.
43. Li P, Liu D, Miao L, et al. A pH-sensitive multifunctional gene carrier assembled via layer-by-layer technique for efficient gene delivery. Int J Nanomedicine. 2012;7:925-939.
44. Kamiya H, Akita H, Harashima H. Pharmacokinetic and pharmacodynamic considerations in gene therapy. Drug Discov Today. 2003;8(21):990-996.
45. Pujols L, Mullol J, Roca-Ferrer J, et al. Expression of glucocorticoid receptor alpha-and beta-isoforms in human cells and tissues. Am J Physiol Cell Physiol. 2002;283(4):C1324-C1331.
46. Shahin V, Albermann L, Schillers H, et al. Steroids dilate nuclear pores imaged with atomic force microscopy. J Cell Physiol. 2005;202(2): 591-601.
47. Schiffelers RM, Metselaar JM, Fens MH, Janssen AP, Molema G, Storm G. Liposome-encapsulated prednisolone phosphate inhibits growth of established tumors in mice. Neoplasia. 2005;7(2):118-127.
48. Banciu M, Schiffelers RM, Fens MH, Metselaar JM, Storm G. Anti-angiogenic effects of liposomal prednisolone phosphate on B16 melanoma in mice. J Control Release. 2006;113(1):1-8.
49. Banciu M, Metselaar JM, Schiffelers RM, Storm G. Liposomal glucocorticoids as tumor-targeted anti-angiogenic nanomedicine in B16 melanoma-bearing mice. J Steroid Biochem Mol Biol. 2008;111(1-2): 101-110.
50. Yu W, Zhang N. Surface modification of nanocarriers for cancer therapy. Curr Nanosci. 2009;5(2):123-134.
51. Torchilin VP. Micellar nanocarriers: pharmaceutical perspectives. Pharm Res. 2007;24(1):1-16.